Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis

Trial Profile

Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms BREEZE-AD3
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 9 Mar 2021 to 19 Jan 2021.
    • 09 Apr 2018 Planned primary completion date changed from 7 Feb 2020 to 21 Dec 2020.
    • 09 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top